(Q46563748)

23 December 2017

title

Time-dependent inhibition of histamine-induced cutaneous responses by oral and intramuscular diphenhydramine and oral fexofenadine (English)

1 reference

23 December 2017

author name string

Douglas H Jones

series ordinal

1

1 reference

23 December 2017

Francisco A Romero

series ordinal

2

1 reference

23 December 2017

Thomas B Casale

series ordinal

3

1 reference

23 December 2017

publication date

1 May 2008

1 reference

23 December 2017

Annals of Allergy, Asthma & Immunology

published in

1 reference

23 December 2017

volume

100

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

452-456

1 reference

23 December 2017

Advances in H1-antihistamines

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Twenty-four hours of activity of cetirizine and fexofenadine in the skin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

H1-antihistaminic activity of cetirizine and fexofenadine in allergic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Skin concentrations of H1-receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

H1-Antihistamines: more relevant than ever in the treatment of allergic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Effects of Fexofenadine, Diphenhydramine, and Alcohol on Driving Performance: A Randomized, Placebo-Controlled Trial in the Iowa Driving Simulator

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

The real-world risk of taking sedating antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Increased risk of serious injury following an initial prescription for diphenhydramine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Clinical comparison of histamine H1-receptor antagonist drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

First do no harm: managing antihistamine impairment in patients with allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Occupational injuries and medication use.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Comparison of cimetidine and diphenhydramine in the treatment of acute urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Histamine antagonists in the treatment of acute allergic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

Famotidine in the treatment of acute urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960470-X

7 January 2021

10.1016/S1081-1206(10)60470-X

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017